ESTRO 2024 - Abstract Book

S2116

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

30. Dai D, Tian Q, Yu G, Shui Y, Jiang H, Wei Q. Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis. Cancers. 2022 Jun 20;14(12):3024.

31. El Houat Y, Massard C, Quillien V, de Crevoisier R, Castelli J. Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers. Adv Radiat Oncol. 2023 Mar 1;8(2):101038.

2397

Digital Poster

Treatment strategies for soft-tissue sarcoma patients: a population-based data analysis

Joerg Andreas Mueller 1 , Karl Stefan Delank 2 , Ian Wittenberg 3 , Alexander Zeh 2 , Dirk Vordermark 1 , Daniel Medenwald 1

1 University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Department of Radiation Oncology, Halle (Saale), Germany. 2 University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Department of Orthopedics, Trauma, and Reconstructive Surgery, Halle (Saale), Germany. 3 Institute of Medical Epidemiology, Biometry, and Informatics, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 8, 06112, Clinical cancer registry, Magdeburg, Germany

Purpose/Objective:

Sarcomas represent a heterogenous group of neoplasms, and there is a lack of data describing treatment patterns in Germany. This paper aims to evaluate patterns of care in a German federal state based on cancer registry data. Our findings will be compared to the German S3 and NCCN guidelines.

Material/Methods:

From 2005 to 2022, we identified patients diagnosed with extremity STS from the German clinical cancer register of Saxony-Anhalt. Sarcoma cases of all clinical or pathological T-stages (T1-T4), all N-stages (N0-1b) and M-stages (0-1a) corresponding to the UICC stages I to IV were considered. Using logistic regression and Cox-proportional hazard analysis, we compared rates of R0 resection among preoperative, postoperative and non RT cohorts and determined predictors of OS and PFS. We included sex, age at diagnosis, histological grade, T-, N- and M-stages, UICC-stage, tumor localization, tumor side, treatment and resection-status as parameters in our regression models.

Results:

34% of patients did not receive RT and 33% received post-operative RT. Rates of R0 resection for postoperative RT and non RT cohorts were 62% and 69%, respectively (p=0,14). Patients treated with adjuvant RT had the best median survival (36 months, 95% CI: 29-54 months). Primary resected patients had a median survival of 27 months (95% CI: 23-42 months). UICC stage II patients treated with adjuvant RT had a benefit in terms of survival compared to surgery alone (HR: 5.20, 95% CI: 1.23-22). Similar to UICC stage I, irradiated patients with UICC stage III STS had no OS benefit. In our multivariate regression model primary resected patients without additional treatment had a higher mortality risk (surgery HR 2.44, 95% CI 1.11-5.36). This effect could not be found in our univariate regression model (surgery HR: 0.99, 95% CI 0.75-1.30).